NEWRON PHARMACEUT. EO-20 Financial Flexibility Index
NEWRON PHARMACEUT. EO-20 financial flexibility index. NEWRON PHARMACEUT. EO-20 (NP5) has a Financial Flexibility Index of 0.63x as of December 2025. Free cash flow of €32.40 Million (operating CF €32.35 Million minus capex €48.00K) represents 1% of total liabilities (€51.19 Million). See NEWRON PHARMACEUT. EO-20 (NP5) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of NEWRON PHARMACEUT. EO-20 (2021–2025)
Financial flexibility index of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. Historical Financial Flexibility Index trend for NEWRON PHARMACEUT. EO-20 across 5 annual periods. Check NEWRON PHARMACEUT. EO-20 (NP5) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
NEWRON PHARMACEUT. EO-20 Financial Flexibility Index by Year (2021–2025)
NEWRON PHARMACEUT. EO-20 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for NEWRON PHARMACEUT. EO-20. For the full cash flow conversion analysis, see NEWRON PHARMACEUT. EO-20 cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.63x | €32.40 Million | €32.35 Million | €51.19 Million | ▲ +324.6% |
| 2024 | -0.28x | €-17.60 Million | €-17.61 Million | €62.45 Million | ▼ -55.2% |
| 2023 | -0.18x | €-10.13 Million | €-10.14 Million | €55.77 Million | ▲ +16.0% |
| 2022 | -0.22x | €-11.07 Million | €-11.09 Million | €51.23 Million | ▲ +10.3% |
| 2021 | -0.24x | €-11.43 Million | €-11.45 Million | €47.38 Million | — |